Menu
← Oncology Approval Tracker
FDA DECISION ·
Beqalzi
sonrotoclax · BeOne Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory mantle cell lymphoma after at least two systemic therapy lines, including a BTK inhibitor.
LAMPGEN ANALYSIS
Why it matters
A BCL-2 inhibitor adds a post-BTK option in mantle cell lymphoma. Response and durability underpin the accelerated decision in a previously treated population.
What research teams should watch
Validate lines and classes of prior therapy and follow protocol-defined tumor lysis monitoring. Track the confirmatory evidence separately from the original single-arm study.
PRIMARY RECORDS